Niagen Bioscience Schedules Q2 2026 Earnings Call Amid Healthy Aging Focus — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience (NASDAQ: NAGE) will report Q2 2026 financial results on August 4, 2026.
The earnings call is scheduled for 4:30 p.m. ET, with a live webcast available.
The company focuses on NAD+ science and healthy aging products, including Tru Niagen® and Niagen™ Plus.
Niagen Bioscience maintains a robust patent portfolio protecting NAD+ precursors.

The big picture

Niagen Bioscience is positioning itself as a leader in the healthy aging sector, leveraging its expertise in NAD+ science. The upcoming earnings call will provide insights into the company's financial health and strategic direction amid increasing competition in the biotech space. The focus on both consumer supplements and pharmaceutical-grade products highlights a dual-pronged approach to market penetration.

What we're watching

Revenue Growth: Whether the company can sustain its position as the number one NAD+ boosting oral supplement in the U.S.
Regulatory Compliance: The pace at which Niagen Bioscience can navigate FDA regulations for its pharmaceutical-grade products.
R&D Progress: How the development of NB4168 under NAD Pharmaceuticals Corp. will impact future growth.